KRAS-mutant NSCLC patients showed a significant benefit in efficacy when treated with first-line chemotherapy combined with immunotherapy, compared to first-line chemotherapy combined with anti-angiogenic therapy. This evidence concerns the gene KRAS and non-small cell lung carcinoma.